


**Product Name** : APX-115  
**Cat. No.** : PC-60410  
**CAS No.** : 1395946-75-4  
**Molecular Formula** : C<sub>17</sub>H<sub>18</sub>ClN<sub>3</sub>O  
**Molecular Weight** : 315.801  
**Target** : NADPH Oxidase (NOX)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Isuzinaxib (APX-115, Ewha 18278) is a first-in-class, orally active, pan-**NADPH oxidase (Nox)** inhibitor with K<sub>i</sub> of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.

Isuzinaxib (APX-115) shows no inhibitory activities on xanthine oxidase and glucose oxidase.

Isuzinaxib (APX-115) inhibits the responses of BMMs to RANKL, including ROS generation, activation of MAPK and NF-κB, and osteoclast cells differentiation.

Isuzinaxib (APX-115) protects db/db mice from renal injury.

## References

Cha JJ, et al. *Lab Invest.* 2017 Apr;97(4):419-431.

Kwon G, et al. *Oncotarget.* 2017 Jun 16. doi: 10.18632/oncotarget.18540.

Joo JH, et al. *Sci Rep.* 2016 Mar 15;6:22389.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com